The relevance of piroxicam for the prevention and treatment of nonmelanoma skin cancer and its precursors

Elena Campione, Evelin Jasmine Paternò, Eleonora Candi, Mattia Falconi, Gaetana Costanza, Laura Diluvio, Alessandro Terrinoni, Luca Bianchi, Augusto Orlandi

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Piroxicam (PXM), a nonsteroidal anti-inflammatory drug, is an enolic benzothiazine and a potent member of the oxicam series. The drug suppresses the synthesis of proinflammatory enzymes, such as cyclooxygenases-1 and -2 (COX-1 and 2), downregulates the production of prostaglandins (PGs) and tromboxanes, and inhibits polyamines production by blocking ornithine decarboxylase induction involved in nonmelanoma skin carcinogenesis. In addition, PXM is able to induce tumor cell apoptosis and suppresses metalloproteinase 2 activities. Skin carcinogenesis is a multistep process in which the accumulation of genetic events leads to a gradually dysplastic cellular expression, deregulation of cell growth, and carcinomatous progression. COX-1 upregulation plays a significant role in PG and vascular epidermal growth factor production supporting tumor growth. Increased level of PGs in premalignant and/or malignant cutaneous tumors is also favored by upregulation of COX-2 and downregulation of the tumor suppressor gene 15-hydroxy-prostaglandin dehydrogenase. Chemoprevention can be a hopeful approach to inhibit carcinoma occurrence before an invasive tumor develops. The chemopreventive effect of nonsteroidal anti-inflammatory drugs on nonmelanoma skin cancers has been established. In this study, we highlighted the different modalities of action of PXM on the pathogenesis of nonmelanoma skin cancer, analyzing and evaluating binding modes and energies between COX-1 or COX-2 and PXM by protein–ligand molecular docking. Our clinical experience about the local use of PXM on actinic keratoses and field cancerization is also reported, confirming its efficacy as target therapy.

Original languageEnglish
Pages (from-to)5843-5850
Number of pages8
JournalDrug Design, Development and Therapy
Volume9
DOIs
Publication statusPublished - Oct 29 2015

Fingerprint

Piroxicam
Skin Neoplasms
Prostaglandins
Neoplasms
Skin
Carcinogenesis
Anti-Inflammatory Agents
Up-Regulation
Down-Regulation
Pharmaceutical Preparations
Actinic Keratosis
Therapeutics
Cyclooxygenase 1
Ornithine Decarboxylase
Chemoprevention
Polyamines
Metalloproteases
Cyclooxygenase 2
Growth
Tumor Suppressor Genes

Keywords

  • Actinic keratosis
  • Binding mode
  • COXs inhibitor
  • Tumor progression

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Pharmacology
  • Drug Discovery

Cite this

The relevance of piroxicam for the prevention and treatment of nonmelanoma skin cancer and its precursors. / Campione, Elena; Paternò, Evelin Jasmine; Candi, Eleonora; Falconi, Mattia; Costanza, Gaetana; Diluvio, Laura; Terrinoni, Alessandro; Bianchi, Luca; Orlandi, Augusto.

In: Drug Design, Development and Therapy, Vol. 9, 29.10.2015, p. 5843-5850.

Research output: Contribution to journalArticle

Campione, E, Paternò, EJ, Candi, E, Falconi, M, Costanza, G, Diluvio, L, Terrinoni, A, Bianchi, L & Orlandi, A 2015, 'The relevance of piroxicam for the prevention and treatment of nonmelanoma skin cancer and its precursors', Drug Design, Development and Therapy, vol. 9, pp. 5843-5850. https://doi.org/10.2147/DDDT.S84849
Campione, Elena ; Paternò, Evelin Jasmine ; Candi, Eleonora ; Falconi, Mattia ; Costanza, Gaetana ; Diluvio, Laura ; Terrinoni, Alessandro ; Bianchi, Luca ; Orlandi, Augusto. / The relevance of piroxicam for the prevention and treatment of nonmelanoma skin cancer and its precursors. In: Drug Design, Development and Therapy. 2015 ; Vol. 9. pp. 5843-5850.
@article{db7110d049c04d0e990b1468584a5052,
title = "The relevance of piroxicam for the prevention and treatment of nonmelanoma skin cancer and its precursors",
abstract = "Piroxicam (PXM), a nonsteroidal anti-inflammatory drug, is an enolic benzothiazine and a potent member of the oxicam series. The drug suppresses the synthesis of proinflammatory enzymes, such as cyclooxygenases-1 and -2 (COX-1 and 2), downregulates the production of prostaglandins (PGs) and tromboxanes, and inhibits polyamines production by blocking ornithine decarboxylase induction involved in nonmelanoma skin carcinogenesis. In addition, PXM is able to induce tumor cell apoptosis and suppresses metalloproteinase 2 activities. Skin carcinogenesis is a multistep process in which the accumulation of genetic events leads to a gradually dysplastic cellular expression, deregulation of cell growth, and carcinomatous progression. COX-1 upregulation plays a significant role in PG and vascular epidermal growth factor production supporting tumor growth. Increased level of PGs in premalignant and/or malignant cutaneous tumors is also favored by upregulation of COX-2 and downregulation of the tumor suppressor gene 15-hydroxy-prostaglandin dehydrogenase. Chemoprevention can be a hopeful approach to inhibit carcinoma occurrence before an invasive tumor develops. The chemopreventive effect of nonsteroidal anti-inflammatory drugs on nonmelanoma skin cancers has been established. In this study, we highlighted the different modalities of action of PXM on the pathogenesis of nonmelanoma skin cancer, analyzing and evaluating binding modes and energies between COX-1 or COX-2 and PXM by protein–ligand molecular docking. Our clinical experience about the local use of PXM on actinic keratoses and field cancerization is also reported, confirming its efficacy as target therapy.",
keywords = "Actinic keratosis, Binding mode, COXs inhibitor, Tumor progression",
author = "Elena Campione and Patern{\`o}, {Evelin Jasmine} and Eleonora Candi and Mattia Falconi and Gaetana Costanza and Laura Diluvio and Alessandro Terrinoni and Luca Bianchi and Augusto Orlandi",
year = "2015",
month = "10",
day = "29",
doi = "10.2147/DDDT.S84849",
language = "English",
volume = "9",
pages = "5843--5850",
journal = "Drug Design, Development and Therapy",
issn = "1177-8881",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - The relevance of piroxicam for the prevention and treatment of nonmelanoma skin cancer and its precursors

AU - Campione, Elena

AU - Paternò, Evelin Jasmine

AU - Candi, Eleonora

AU - Falconi, Mattia

AU - Costanza, Gaetana

AU - Diluvio, Laura

AU - Terrinoni, Alessandro

AU - Bianchi, Luca

AU - Orlandi, Augusto

PY - 2015/10/29

Y1 - 2015/10/29

N2 - Piroxicam (PXM), a nonsteroidal anti-inflammatory drug, is an enolic benzothiazine and a potent member of the oxicam series. The drug suppresses the synthesis of proinflammatory enzymes, such as cyclooxygenases-1 and -2 (COX-1 and 2), downregulates the production of prostaglandins (PGs) and tromboxanes, and inhibits polyamines production by blocking ornithine decarboxylase induction involved in nonmelanoma skin carcinogenesis. In addition, PXM is able to induce tumor cell apoptosis and suppresses metalloproteinase 2 activities. Skin carcinogenesis is a multistep process in which the accumulation of genetic events leads to a gradually dysplastic cellular expression, deregulation of cell growth, and carcinomatous progression. COX-1 upregulation plays a significant role in PG and vascular epidermal growth factor production supporting tumor growth. Increased level of PGs in premalignant and/or malignant cutaneous tumors is also favored by upregulation of COX-2 and downregulation of the tumor suppressor gene 15-hydroxy-prostaglandin dehydrogenase. Chemoprevention can be a hopeful approach to inhibit carcinoma occurrence before an invasive tumor develops. The chemopreventive effect of nonsteroidal anti-inflammatory drugs on nonmelanoma skin cancers has been established. In this study, we highlighted the different modalities of action of PXM on the pathogenesis of nonmelanoma skin cancer, analyzing and evaluating binding modes and energies between COX-1 or COX-2 and PXM by protein–ligand molecular docking. Our clinical experience about the local use of PXM on actinic keratoses and field cancerization is also reported, confirming its efficacy as target therapy.

AB - Piroxicam (PXM), a nonsteroidal anti-inflammatory drug, is an enolic benzothiazine and a potent member of the oxicam series. The drug suppresses the synthesis of proinflammatory enzymes, such as cyclooxygenases-1 and -2 (COX-1 and 2), downregulates the production of prostaglandins (PGs) and tromboxanes, and inhibits polyamines production by blocking ornithine decarboxylase induction involved in nonmelanoma skin carcinogenesis. In addition, PXM is able to induce tumor cell apoptosis and suppresses metalloproteinase 2 activities. Skin carcinogenesis is a multistep process in which the accumulation of genetic events leads to a gradually dysplastic cellular expression, deregulation of cell growth, and carcinomatous progression. COX-1 upregulation plays a significant role in PG and vascular epidermal growth factor production supporting tumor growth. Increased level of PGs in premalignant and/or malignant cutaneous tumors is also favored by upregulation of COX-2 and downregulation of the tumor suppressor gene 15-hydroxy-prostaglandin dehydrogenase. Chemoprevention can be a hopeful approach to inhibit carcinoma occurrence before an invasive tumor develops. The chemopreventive effect of nonsteroidal anti-inflammatory drugs on nonmelanoma skin cancers has been established. In this study, we highlighted the different modalities of action of PXM on the pathogenesis of nonmelanoma skin cancer, analyzing and evaluating binding modes and energies between COX-1 or COX-2 and PXM by protein–ligand molecular docking. Our clinical experience about the local use of PXM on actinic keratoses and field cancerization is also reported, confirming its efficacy as target therapy.

KW - Actinic keratosis

KW - Binding mode

KW - COXs inhibitor

KW - Tumor progression

UR - http://www.scopus.com/inward/record.url?scp=84946078672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946078672&partnerID=8YFLogxK

U2 - 10.2147/DDDT.S84849

DO - 10.2147/DDDT.S84849

M3 - Article

AN - SCOPUS:84946078672

VL - 9

SP - 5843

EP - 5850

JO - Drug Design, Development and Therapy

JF - Drug Design, Development and Therapy

SN - 1177-8881

ER -